IBDEI0ZL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15877,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,15877,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,15878,0)
 ;;=L40.4^^88^869^160
 ;;^UTILITY(U,$J,358.3,15878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15878,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,15878,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,15878,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,15879,0)
 ;;=L40.8^^88^869^292
 ;;^UTILITY(U,$J,358.3,15879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15879,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,15879,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,15879,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,15880,0)
 ;;=L40.9^^88^869^294
 ;;^UTILITY(U,$J,358.3,15880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15880,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,15880,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,15880,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,15881,0)
 ;;=L50.9^^88^869^326
 ;;^UTILITY(U,$J,358.3,15881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15881,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,15881,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,15881,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,15882,0)
 ;;=L53.8^^88^869^150
 ;;^UTILITY(U,$J,358.3,15882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15882,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,15882,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,15882,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,15883,0)
 ;;=L53.9^^88^869^149
 ;;^UTILITY(U,$J,358.3,15883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15883,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,15883,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,15883,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,15884,0)
 ;;=L54.^^88^869^148
 ;;^UTILITY(U,$J,358.3,15884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15884,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,15884,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,15884,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,15885,0)
 ;;=L56.0^^88^869^142
 ;;^UTILITY(U,$J,358.3,15885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15885,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,15885,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,15885,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,15886,0)
 ;;=L56.1^^88^869^141
 ;;^UTILITY(U,$J,358.3,15886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15886,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,15886,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,15886,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,15887,0)
 ;;=L56.2^^88^869^274
 ;;^UTILITY(U,$J,358.3,15887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15887,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,15887,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,15887,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,15888,0)
 ;;=L56.3^^88^869^308
 ;;^UTILITY(U,$J,358.3,15888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15888,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,15888,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,15888,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,15889,0)
 ;;=L57.0^^88^869^13
 ;;^UTILITY(U,$J,358.3,15889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15889,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,15889,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,15889,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,15890,0)
 ;;=L60.0^^88^869^164
 ;;^UTILITY(U,$J,358.3,15890,1,0)
 ;;=^358.31IA^4^2
